AstraZeneca/Merck's Lynparza gets EMA panel's greenlight for expanded use in prostate cancer
Waldemarus


A panel of the European Medicines Agency (EMA) recommended the expanded approval of AstraZeneca (NASDAQ:AZN) and Merck's (NYSE:MRK) blockbuster cancer drug Lynparza.
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a new indication Lynparza (olaparib), in combination with abiraterone and prednisone or prednisolone, to treat adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

Lynparza is already approved to treat certain patients with types of breast, ovarian, pancreatic, and prostate cancers in the EU.
The European Commission, which generally follows the opinion of the CHMP, will now decide on the change to the terms of the marketing authorization of Lynparza.